Page last updated: 2024-11-07

tc 81

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID119153
SCHEMBL ID677408
MeSH IDM0200774

Synonyms (16)

Synonym
tc-81
palonidipine hydrochloride
palonidipine.hcl
2,2-dimethyl-3-[methyl(phenylmethyl)amino]propyl methyl 4-(2-fluoro-5-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
96515-74-1
tc 81
3,5-pyridinedicarboxylic acid, 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-, 2,2-dimethyl-3-(methyl(phenylmethyl)amino)propyl methyl ester, monohydrochloride
ccris 8938
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-fluoro-5-nitrophenyl)-, 2,2-dimethyl-3-(methyl(phenylmethyl)amino)propyl methyl ester, monohydrochloride
9d73pq95uj ,
palonidipine hcl
unii-9d73pq95uj
SCHEMBL677408
DTXSID5021099
3,5-pyridinedicarboxylic acid, 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-, 3-[2,2-dimethyl-3-[methyl(phenylmethyl)amino]propyl] 5-methyl ester, hydrochloride (1:1)
3,5-pyridinedicarboxylic acid, 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-, 2,2-dimethyl-3-[methyl(phenylmethyl)amino]propyl methyl ester, monohydrochloride

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" After oral administration, 14C-TC-81 was rapidly and well absorbed from the gastrointestinal tract."( Absorption, plasma concentration, and excretion after single administration of 14C-(+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats and dogs.
Arizono, H; Ishii, S; Kiyoki, M; Matsunaga, T; Mochizuki, T; Okabe, K; Sato, H; Sato, J; Tanabe, H; Taneda, M, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Tolerance of the antihypertensive effect of TC-81 in long-term daily dosing and the rebound phenomenon after discontinuance of the treatment were not observed in hypertensive rats."( Antihypertensive effect of the new calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl-methyl-4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats.
Aoki, K; Kishimoto, T; Naruchi, T; Okamiya, Y; Sunakawa, K; Takeshita, T; Tanabe, H, 1992
)
0.28
" Tolerance of the antihypertensive effect of TC-81 in daily dosing for 2 weeks and the rebound phenomena after discontinuance of the treatment were not observed in RHD."( Antihypertensive effect of the new dihydropyridine calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedica rbo xylate hydrochloride in dogs.
Aoki, K; Kishimoto, T; Naruchi, T; Okamiya, Y; Sunakawa, K; Takeshita, T; Tanabe, H, 1992
)
0.28
"5 h after dosing in every dose examined."( Absorption, plasma concentration, and excretion after single administration of 14C-(+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats and dogs.
Arizono, H; Ishii, S; Kiyoki, M; Matsunaga, T; Mochizuki, T; Okabe, K; Sato, H; Sato, J; Tanabe, H; Taneda, M, 1992
)
0.28
" The radioactivity in the various tissues declined slowly comparing to the plasma but at 96 h after dosing the radioactivity was detected only in the liver."( Distribution to and elimination from tissues following a single or repeated administration of 14C-(+-)-3-(benzyl-methylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedica rbo xylate hydrochloride in rats.
Ishii, S; Kiyoki, M; Matsunaga, T; Mochizuki, T; Okabe, K; Sato, J; Takeshita, T; Tanabe, H, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.98 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index61.15 (26.88)
Search Engine Supply Index3.78 (0.95)

This Compound (29.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]